Neurofibromatosis Type 1 (NF1) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | NFlection, Novartis, Fosun Pharma

Posted on
by

Neurofibromatosis Type 1 (NF1) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | NFlection, Novartis, Fosun Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Neurofibromatosis Type 1 therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Neurofibromatosis Type 1 (NF1) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Neurofibromatosis Type 1 Market. 

The Neurofibromatosis Type 1 Pipeline report embraces in-depth commercial, regulatory, and Neurofibromatosis Type 1 clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Neurofibromatosis Type 1 drug, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Neurofibromatosis Type 1 (NF1)  Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Neurofibromatosis Type 1 treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Neurofibromatosis Type 1 therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Neurofibromatosis Type 1 companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Neurofibromatosis Type 1 drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Neurofibromatosis Type 1 therapeutic market.

Neurofibromatosis Type 1 (NF1) Therapeutics Landscape

Neurofibromatosis type 1 (NF1) is a common cancer predisposition genetic disease that is associated with significant morbidity and mortality. There is currently no cure for neurofibromatosis type 1 (NF1), so management involves regular monitoring and treatment for any problems as and when they occur.

While no treatment can reverse NF1, its signs and symptoms can be addressed. Tumors, in particular, may warrant chemotherapy, radiation, surgery, or a combination of treatments. About 60% of people with NF1, symptoms are mild and can be monitored without needing treatment. Expert evaluation and a multispecialty approach at a specialized clinic can help a person with NF1 manage symptoms and improve quality of life.

There are approx. 10+ key companies are developing therapies for Neurofibromatosis Type 1. Currently, SpringWorks Therapeutics is leading the therapeutics market with its Neurofibromatosis Type 1 drug candidates in the most advanced stage of clinical development.

Neurofibromatosis Type 1 Companies Actively Working in the Therapeutic Market Include:

  • NFlection Therapeutics

  • SpringWorks Therapeutics

  • Novartis

  • Array BioPharma

  • Shanghai Fosun Pharmaceutical Development Co, Ltd.

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

And Many Others

Emerging and Marketed Neurofibromatosis Type 1 Drug Covered in the Report Include:

  • Mirdametinib: SpringWorks Therapeutics

  • NFX-179: NFlection Therapeutics

  • FH1701: Fosun Pharmaceutical

  • HLX-1502: Healx Ltd.

  • Selumetinib: AstraZeneca/Merck Sharp & Dohme LLC

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Neurofibromatosis Type 1 Companies Working in the Market @

https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-pipeline-insight

Analysis of Emerging Neurofibromatosis Type 1 Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Neurofibromatosis Type 1 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Neurofibromatosis Type 1 Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Neurofibromatosis Type 1 Treatment Patterns

4. Neurofibromatosis Type 1 – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Neurofibromatosis Type 1 Late Stage Products (Phase-III)

7. Neurofibromatosis Type 1 Mid-Stage Products (Phase-II)

8. Neurofibromatosis Type 1 Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neurofibromatosis Type 1 Discontinued Products

13. Neurofibromatosis Type 1 Product Profiles

14. Major Neurofibromatosis Type 1 Companies in the Market

15. Key Products in the Neurofibromatosis Type 1 Therapeutics Segment

16. Dormant and Discontinued Products

17. Neurofibromatosis Type 1 Unmet Needs

18. Neurofibromatosis Type 1 Future Perspectives

19. Neurofibromatosis Type 1 Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Neurotrophic Keratopathy Market

“Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Neurotrophic Keratopathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Neurotrophic Keratopathy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research